CONCLUSION: Risk stratification of CRC using a RPT showed increased screening uptake. Future research is needed to understand which components of this complex intervention worked to bring about improved outcomes. →

The aim of this study was to compare the efficacy and safety of 755-nm picosecond alexandrite laser and topical tranexamic acid (TTA) combination therapy vs. laser monotherapy, for the treatment of melasma and facial rejuvenation. This multicentre, randomized, double-blinded, split-face study enrolled 37 patients who presented with melasma and photoageing. Facial halves were randomized to… →

Remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, has shown efficacy and favourable safety in the REMIX-1/2 studies in patients with chronic spontaneous urticaria (CSU). Herein, we report the impact of remibrutinib treatment on Work Productivity and Activity Impairment (WPAI) and Dermatology Life Quality Index (DLQI) outcomes. REMIX-1 and REMIX-2 were identical, phase III,… →

Recruiting clinical trial participants to time and target can be challenging. Innovative recruitment strategies, such as facilitating participant self-referral, can be beneficial. The BEACON trial is a national multicentre phase IV assessor-blinded randomized controlled trial comparing the effectiveness, tolerability and cost-effectiveness of ciclosporin, methotrexate and dupilumab in adults with moderate-to-severe eczema. The aim of this… →

The aim of this study was to test whether a weekly bath or shower improves eczema symptoms compared with a daily bath or shower for people with eczema. This was an online, pragmatic, superiority randomized controlled trial, codesigned by people with eczema (citizen scientists), healthcare professionals and researchers. The Eczema Bathing Study is the first… →

Amlitelimab is a fully human, nondepleting anti-OX40 ligand (OX40L) monoclonal antibody under investigation for atopic dermatitis (AD). Lesions on the head and neck are difficult to treat due to multiple triggers and generally have lower response to treatments than lesions observed in other body regions. Here we report the impact of amlitelimab on Eczema Area… →

Treatment options for moderate-to-severe alopecia areata (AA) have limited efficacy. Methotrexate, a conventional immunosuppressant, has been used for AA, while Janus kinase inhibitors like tofacitinib have shown promising results. Our aim was to compare the efficacy and safety of oral tofacitinib and methotrexate in treating moderate-to-severe AA. This study recruited 36 patients with moderate-to-severe AA,… →

Treatment options for moderate-to-severe alopecia areata (AA) have limited efficacy. Methotrexate, a conventional immunosuppressant, has been used for AA, while Janus kinase inhibitors like tofacitinib have shown promising results. Our aim was to compare the efficacy and safety of oral tofacitinib and methotrexate in treating moderate-to-severe AA. This study recruited 36 patients with moderate-to-severe AA,… →

CONCLUSION: Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI. →

CONCLUSIONS: Both the ISO-SR and ISO-MR exercises to volitional fatigue reduced pain sensitivity in patients with knee osteoarthritis. Neither exercise volume changed clinical pain intensity. →